ClinicalTrials.gg
CompletedNCT02600507Updated May 17, 2023Results posted

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

A Phase 3 interventional study of Lumateperone (ITI-007) and Placebo in Bipolar Depression, sponsored by Intra-Cellular Therapies, Inc.. Completed at 71 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
529
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.

Enrollment
5th of 36
529 · median 300
Started
2016
with 1 other
Phase 3
28 of 39
2 open now
Registered
30th of 39
by date

Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 5th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2016, is one of 28 in phase 3, and was the 30th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Bipolar Disorder by Johnson & Johnson, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder
  • experiencing a current major depressive episode
  • treatment with either lithium or valproate and inadequate therapeutic response of depressive symptoms

Exclusion criteria

Exclusion Criteria:

  • any subject unable to provide
  • any female subject who is pregnant or breastfeeding
  • any subject judged to be medically inappropriate for study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
529 participants (actual)

Study arms

  • Experimental
    Lumateperone 28 mg (ITI-007 40 mg tosylate)

    Lumateperone 28 mg (ITI-007 40 mg tosylate) administered orally as capsules once daily for 6 weeks

    Drug: Lumateperone (ITI-007)

  • Experimental
    Lumateperone 42 mg (ITI-007 60 mg tosylate)

    Lumateperone 42 mg (ITI-007 60 mg tosylate) administered orally as capsules once daily for 6 weeks

    Drug: Lumateperone (ITI-007)

  • Placebo comparator
    Placebo

    Placebo administered orally as visually-matched capsules once daily for 6 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: Baseline to Day 43

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score

    The Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score is a clinician-rated scale that measures the patient's current state of depression from 1 (not ill at all) to 7 (among the most extremely ill).

    Time frame: Baseline to Day 43

07

Results

Posted May 17, 2023

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Started176177175
Completed147133150
Not completed294425
Withdrew: Adverse event3155
Withdrew: Lack of efficacy385
Withdrew: Lost to follow-up352
Withdrew: Protocol violation1244
Withdrew: Physician decision101
Withdrew: Withdrawal by subject7117
Withdrew: Other011

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
Baseline to Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scaleLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-16.2 ± 0.79-16.9 ± 0.81-14.5 ± 0.79
Statistical analysis
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.021 · Least squares mean difference: -2.4 · 95% CI -4.42 to -0.37
  • Lumateperone 28 mg (ITI-007 40 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.099 · Least squares mean difference: -1.7 · 95% CI -3.65 to 0.32
SecondaryChange From Baseline in Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score

The Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score is a clinician-rated scale that measures the patient's current state of depression from 1 (not ill at all) to 7 (among the most extremely ill).

Time frame:
Baseline to Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score
score on a scaleLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Change From Baseline in Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score-1.7 ± 0.09-1.8 ± 0.10-1.5 ± 0.09
Statistical analysis
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.008 · Least squares mean difference: -0.3 · 95% CI -0.59 to -0.09
  • Lumateperone 28 mg (ITI-007 40 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.040 · Least squares mean difference: -0.3 · 95% CI -0.50 to -0.01

Adverse events

Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 28 mg (ITI-007 40 mg Tosylate)0/176 (0%)0/176 (0%)50/176 (28.4%)
Lumateperone 42 mg (ITI-007 60 mg Tosylate)0/177 (0%)1/177 (0.6%)47/177 (26.6%)
Placebo0/175 (0%)0/175 (0%)28/175 (16%)
Most frequent serious events
Most frequent serious events
EventLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Toxicity to various agentsInjury, poisoning and procedural complications0/1761/1770/175
Most frequent other events
Most frequent other events
EventLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
HeadacheNervous system disorders23/17620/17720/175
SomnolenceNervous system disorders13/17620/1776/175
DizzinessNervous system disorders18/17619/1774/175
NauseaGastrointestinal disorders10/17615/1777/175

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Mean44.0 ± 13.5644.7 ± 12.6045.1 ± 12.9344.6 ± 13.02
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Female10110998308
Male756877220
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
White153156157466
Black or African American22201456
Asian0033
Other1113
Region of Enrollment
Region of Enrollment(participants)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
United States595856173
Ukraine21211557
Bulgaria494548142
Serbia16162052
Russia313736104
Montgomery-Asberg Depression Rating Scale (MADRS)
Montgomery-Asberg Depression Rating Scale (MADRS)(units on a scale)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Mean32.5 ± 5.5532.3 ± 4.9632.2 ± 5.2332.3 ± 5.24
08

Study locations

71 sites
  • Clinical Site
    Rogers, Arkansas, United States
  • Clinical Site
    Cerritos, California, United States
  • Clinical Site
    Costa Mesa, California, United States
  • Clinical Site
    Culver City, California, United States
  • Clinical Site
    Garden Grove, California, United States
  • Clinical Site
    Glendale, California, United States
  • Clinical Site
    Lemon Grove, California, United States
  • Clinical Site
    Oceanside, California, United States
  • Clinical Site
    Pico Rivera, California, United States
  • Clinical Site
    Riverside, California, United States
  • Clinical Site
    San Diego, California, United States
  • Clinical Site
    Santa Rosa, California, United States
  • Clinical Site
    Sherman Oaks, California, United States
  • Clinical Site
    Temecula, California, United States
  • Clinical Site
    Jacksonville, Florida, United States
  • Clinical Site
    Lauderhill, Florida, United States
  • Clinical Site
    Miami, Florida, United States
  • Clinical Site
    Orange City, Florida, United States
  • Clinical Site
    Orlando, Florida, United States
  • Clinical Site
    Atlanta, Georgia, United States
  • Clinical Site
    Savannah, Georgia, United States
  • Clinical Site
    Chicago, Illinois, United States
  • Clinical Site
    Lake Charles, Louisiana, United States
  • Clinical Site
    Baltimore, Maryland, United States
  • Clinical Site
    O'Fallon, Missouri, United States
  • Clinical Site
    Saint Louis, Missouri, United States
  • Clinical Site
    Las Vegas, Nevada, United States
  • Clinical Site
    Berlin, New Jersey, United States
  • Clinical Site
    Cherry Hill, New Jersey, United States
  • Clinical Site
    Toms River, New Jersey, United States
  • Clinical Site
    Cedarhurst, New York, United States
  • Clinical Site
    New York, New York, United States
  • Clinical Site
    Rochester, New York, United States
  • Clinical Site
    Staten Island, New York, United States
  • Clinical Site
    Charlotte, North Carolina, United States
  • Clinical Site
    Cincinnati, Ohio, United States
  • Clinical Site
    Dayton, Ohio, United States
  • Clinical Site
    Garfield Heights, Ohio, United States
  • Clinical Site
    Allentown, Pennsylvania, United States
  • Clinical Site
    Philadelphia, Pennsylvania, United States
  • Clinical Site
    The Woodlands, Texas, United States
  • Clinical Site
    Everett, Washington, United States
  • Clinical Site
    Burgas, Bulgaria
  • Clinical Site
    Kardzhali, Bulgaria
  • Clinical Site
    Lovech, Bulgaria
  • Clinical Site
    Pleven, Bulgaria
  • Clinical Site
    Plovdiv, Bulgaria
  • Clinical Site
    Ruse, Bulgaria
  • Clinical Site
    Sofia, Bulgaria
  • Clinical Site
    Varna, Bulgaria
  • Clinical Site
    Veliko Tarnovo, Bulgaria
  • Clinical Site
    Vratsa, Bulgaria
  • Clinical Site
    Moscow, Russian Federation
  • Clinical Site
    Nizhny Novgorod, Russian Federation
  • Clinical Site
    Omsk, Russian Federation
  • Clinical Site
    Saint Petersburg, Russian Federation
  • Clinical Site
    Samara, Russian Federation
  • Clinical Site
    Saratov, Russian Federation
  • Clinical Site
    Tomsk, Russian Federation
  • Clinical Site
    Belgrade, Serbia
  • Clinical Site
    Kovin, Serbia
  • Clinical Site
    Novi Sad, Serbia
  • Clinical Site
    Sumadija, Serbia
  • Clinical Site
    Ivano-Frankivs'k, Ukraine
  • Clinical Site
    Kharkiv, Ukraine
  • Clinical Site
    Kropyvnytskyi, Ukraine
  • Clinical Site
    Odesa, Ukraine
  • Clinical Site
    Poltava, Ukraine
  • Clinical Site
    Smila, Ukraine
  • Clinical Site
    Vasylkiv, Ukraine
  • Clinical Site
    Vinnytsia, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jul 2020, 51 months.

Results were first posted in May 2023, 2 years 10 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 51 months is above that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2015
First posted
Nov 9, 2015
StartActual
Mar 7, 2016
Primary completionActual
Jul 2, 2020
CompletionActual
Jul 2, 2020
Results first posted
May 17, 2023
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02600507
Responsible party
Sponsor
First posted
Nov 9, 2015
Start date
Mar 7, 2016
Primary completion
Jul 2, 2020
Completion
Jul 2, 2020
Results posted
May 17, 2023
Last update
May 17, 2023

Study contacts

Susan Kozauer, MD
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion